Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles.

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. Abstract Text:

Elizabeth P Ryan,Christine M Malboeuf,Matthew Bernard,Robert C Rose,Richard P Phipps,

Vaccination to generate protective humoral immunity against infectious disease is becoming increasingly important due to emerging strains of virus, poorly immunogenic vaccines, and the threat of bioterrorism. We demonstrate that cyclooxygenase-2 (Cox-2) is crucial for optimal Ab responses to a model vaccine, human papillomavirus type 16 virus-like particles (HPV 16 VLPs). Cox-2-deficient mice produce 70% less IgG, 50% fewer Ab-secreting cells, and 10-fold less neutralizing Ab to HPV 16 VLP vaccination compared with wild-type mice. The reduction in Ab production by Cox-2(-/-) mice was partially due to a decrease in class switching. SC-58125, a structural analog of the Cox-2-selective inhibitor Celebrex reduced by approximately 70% human memory B cell differentiation to HPV 16 VLP IgG-secreting cells. The widespread use of nonsteroidal anti-inflammatory drugs and Cox-2-selective inhibitory drugs may therefore reduce vaccine efficacy, especially when vaccines are poorly immunogenic or the target population is poorly responsive to immunization.

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. Publishing Authors By Initials

EP Ryan,CM Malboeuf,M Bernard,RC Rose,RP Phipps,

For similar viruses: virion research abstracts see: viruses: virion research

PUBMED ID PMID:

MEDLINE DATE:

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of immunology (Baltimore, Md. : 1950)

VOLUME: 177

Page Numbers: 7811-9

Journal Abbreviation: J. Immunol.

ISSN: 0022-1767

DAY: 1

MONTH: Dec

YEAR: 2006

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985117

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. Keywords Mesh Terms:

KEYWORDS: Virion

MESH TERMS: immunology

Chemical & Substance for Abstract: Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. Information

Substance Name: Cyclooxygenase 2

Registry Number: EC 1.14.99.1

Grant and Affiliation Information for Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles.

AFFILIATION: Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.

Country: United States

AGENCY: United States NIAID

GRANT: T32 AI 007169

ACRONYM: AI

MEDLINETA: J Immunol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles Related Publications

• Accessing Care: Use of a Specialized Women's Emergency Care Facility for Nonemergent Problems.
• Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes.
• Adaptive style and differences in parent and child report of health-related quality of life in children with cancer.
• Adaptive style in children with cancer: implications for a positive psychology approach.
• Chronic poverty and childhood asthma in the Maritimes versus the rest of Canada.
• Consequences of inadequate sex education in the United States.
• CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production.
• Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells.
• Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles.
• Effect of soy protein on testosterone levels.
• Effective and organ doses from thoron decay products at different ages.
• Effects of corn silage derived from a genetically modified variety containing two transgenes on feed intake, milk production, and composition, and the absence of detectable transgenic deoxyribonucleic acid in milk in Holstein dairy cows.
• Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: implications for vulvar vestibulitis.
• Evaluation of Bacillus anthracis thymidine kinase as a potential target for the development of antibacterial nucleoside analogs.
• Getting a piece of the pie? The economic boom of the 1990s and declining teen birth rates in the United States.
• Intrapartum group B streptococci prophylaxis in patients reporting a penicillin allergy.
• Optimization of retardance for a complete Stokes polarimeter.
• Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles.
• Physiological control of airway mucus secretion.
• Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease.
• Pollutant-induced airway abnormalities.
• Quantitative measurement of anthrax toxin receptor messenger RNA in primary mononuclear phagocytes.
• Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion.
• Self-report of somatic symptoms in survivors of childhood cancer: effects of adaptive style.
• The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.
• The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms.
• The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands.
• The role of the clinical nurse specialist in promoting evidence-based practice and effecting positive patient outcomes.
• The use of Biobrane((R)) by burn units in the United Kingdom: A national study.
• [Not Available.]